Abstract |
A clinical, retrospective and non-comparative study was undertaken to assess the clinical efficacy and tolerability of azithromycin in the treatment of community-acquired pneumonia caused by Legionella pneumophila. A total of 16 patients with a serologically confirmed diagnosis of Legionnaires' diseases were included. Azithromycin was administered orally at a total dose of 1.5 g for either 3 or 5 days. All patients were no side-effects requiring discontinuation of the treatment. Further increase of abnormal baseline liver function was recorded in 2 patients and in 1 patient mild, transient eosinophilia. Equal clinical efficacy and tolerability were observed with the 3- and 5-day dosage regimen. These results indicate that azithromycin given at a standard dose of 1.5 g is effective and well tolerated in the treatment of Legionnaires' disease.
|
Authors | I Kuzman, I Soldo, S Schönwald, J Culig |
Journal | Scandinavian journal of infectious diseases
(Scand J Infect Dis)
Vol. 27
Issue 5
Pg. 503-5
( 1995)
ISSN: 0036-5548 [Print] England |
PMID | 8588143
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Anti-Bacterial Agents
- Azithromycin
|
Topics |
- Adult
- Anti-Bacterial Agents
(adverse effects, therapeutic use)
- Azithromycin
(adverse effects, therapeutic use)
- Community-Acquired Infections
(drug therapy)
- Drug Tolerance
- Eosinophilia
(chemically induced)
- Humans
- Legionnaires' Disease
(drug therapy)
- Liver
(drug effects)
- Male
- Middle Aged
- Retrospective Studies
|